A Novel Application of Maleimide for Advanced Drug Delivery: in Vitro and in Vivo Evaluation of Maleimide-modified PH-sensitive Liposomes

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2013 Oct 22

PMID 24143089

Citations 8

Authors

Tianshu Li

Shinji Takeoka

Affiliations

Soon will be listed here.

Abstract

Maleimide is a stable and easy-to-handle moiety that rapidly and covalently conjugates thiol groups of cysteine residues in proteins or peptides. Herein, we use maleimide to modify the surface of liposomes in order to obtain an advanced drug delivery system. Employing a small amount (0.3 mol%) of maleimide-polyethylene glycol (PEG) to modify the surface of the liposomes M-GGLG-liposomes, composed of 1,5-dihexadecyl N,N-diglutamyl-lysyl-L-glutamate (GGLG)/cholesterol/poly(ethylene glycol) 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (PEG5000-DSPE)/maleimide-PEG5000-Glu2C18 at a molar ratio of 5:5:0.03:0.03, drug delivery efficiency was remarkably improved both in vitro and in vivo compared to unmodified liposomes (GGLG-liposomes, composed of GGLG/cholesterol/PEG5000-DSPE/PEG5000-Glu2C18 at a molar ratio of 5:5:0.03:0.03). Moreover, this modification did not elicit any detectable increase in cytotoxicity. The maleimide-modification did not alter the physical characteristics of the liposomes such as size, zeta potential, pH sensitivity, dispersibility and drug encapsulation efficiency. However, M-GGLG-liposomes were more rapidly (≥2-fold) internalized into HeLa, HCC1954, and MDA-MB-468 cells compared to GGLG-liposomes. In vivo, M-GGLG-liposomes encapsulating doxorubicin (M-GGLG-DOX-liposomes) also showed a more potent antitumor effect than GGLG-DOX-liposomes and the widely used 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)-DOX-liposomes after two subcutaneous injections around breast cancer tissue in mice. The biodistribution of liposomes in this model was observed using an in vivo imaging system, which showed that M-GGLG-liposomes were present for significantly longer at the injection site compared to GGLG-liposomes. The outstanding biological functions of the maleimide-modified liposomes as a novel drug delivery system make them ideally suited to a wide range of applications.

Citing Articles

Development of Stable, Maleimide-Functionalized Peptidoliposomes Against SARS-CoV-2.

Michel O, Kaczorowska A, Matusewicz L, Piorkowska K, Golec M, Fus W Int J Mol Sci. 2025; 26(4).

PMID: 40004092 PMC: 11855074. DOI: 10.3390/ijms26041629.

Peptide and Protein Cysteine Modification Enabled by Hydrosulfuration of Ynamide.

Wang C, Zhao Z, Ghadir R, Yang D, Zhang Z, Ding Z ACS Cent Sci. 2024; 10(9):1742-1754.

PMID: 39345815 PMC: 11428291. DOI: 10.1021/acscentsci.4c01148.

The Emerging Roles of Nanocarrier Drug Delivery System in Treatment of Intervertebral Disc Degeneration-Current Knowledge, Hot Spots, Challenges and Future Perspectives.

Hu Y, Yang R, Liu S, Song Z, Wang H Drug Des Devel Ther. 2024; 18:1007-1022.

PMID: 38567254 PMC: 10986407. DOI: 10.2147/DDDT.S448807.

Maleimide-Functionalized Liposomes: Prolonged Retention and Enhanced Efficacy of Doxorubicin in Breast Cancer with Low Systemic Toxicity.

Tang C, Yin D, Liu T, Gou R, Fu J, Tang Q Molecules. 2022; 27(14).

PMID: 35889500 PMC: 9320254. DOI: 10.3390/molecules27144632.

Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC.

Kong L, Zhang S, Chu J, Liu X, Zhang L, He S Int J Nanomedicine. 2020; 15:6451-6468.

PMID: 32922011 PMC: 7457883. DOI: 10.2147/IJN.S258906.

References

Bae Y, Park K . Targeted drug delivery to tumors: myths, reality and possibility. J Control Release. 2011; 153(3):198-205. PMC: 3272876. DOI: 10.1016/j.jconrel.2011.06.001. View

Ong W, Yang Y, Cruciano A, McCarley R . Redox-triggered contents release from liposomes. J Am Chem Soc. 2008; 130(44):14739-44. PMC: 2590935. DOI: 10.1021/ja8050469. View

Bruynzeel A, Niessen H, Bronzwaer J, van der Hoeven J, Berkhof J, Bast A . The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br J Cancer. 2007; 97(8):1084-9. PMC: 2360436. DOI: 10.1038/sj.bjc.6603994. View

Allen T . Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci. 1994; 15(7):215-20. DOI: 10.1016/0165-6147(94)90314-x. View

Aubry S, Burlina F, Dupont E, Delaroche D, Joliot A, Lavielle S . Cell-surface thiols affect cell entry of disulfide-conjugated peptides. FASEB J. 2009; 23(9):2956-67. DOI: 10.1096/fj.08-127563. View

Kichler A, Remy J, Boussif O, Frisch B, Boeckler C, Behr J . Efficient gene delivery with neutral complexes of lipospermine and thiol-reactive phospholipids. Biochem Biophys Res Commun. 1995; 209(2):444-50. DOI: 10.1006/bbrc.1995.1522. View

Maeda H . The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul. 2001; 41:189-207. DOI: 10.1016/s0065-2571(00)00013-3. View

Schroeder A, Honen R, Turjeman K, Gabizon A, Kost J, Barenholz Y . Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release. 2009; 137(1):63-8. DOI: 10.1016/j.jconrel.2009.03.007. View

Holme M, Fedotenko I, Abegg D, Althaus J, Babel L, Favarger F . Shear-stress sensitive lenticular vesicles for targeted drug delivery. Nat Nanotechnol. 2012; 7(8):536-43. DOI: 10.1038/nnano.2012.84. View

10.

Huang S . Liposomes in ultrasonic drug and gene delivery. Adv Drug Deliv Rev. 2008; 60(10):1167-76. DOI: 10.1016/j.addr.2008.03.003. View

11.

Obata Y, Tajima S, Takeoka S . Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J Control Release. 2009; 142(2):267-76. DOI: 10.1016/j.jconrel.2009.10.023. View

12.

Liang X, Yue X, Dai Z, Kikuchi J . Photoresponsive liposomal nanohybrid cerasomes. Chem Commun (Camb). 2011; 47(16):4751-3. DOI: 10.1039/c1cc00063b. View

13.

Oussoren C, Zuidema J, Crommelin D, Storm G . Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose. Biochim Biophys Acta. 1997; 1328(2):261-72. DOI: 10.1016/s0005-2736(97)00122-3. View

14.

Oussoren C, VELINOVA M, Scherphof G, Van Der Want J, van Rooijen N, Storm G . Lymphatic uptake and biodistribution of liposomes after subcutaneous injection . IV. Fate of liposomes in regional lymph nodes. Biochim Biophys Acta. 1998; 1370(2):259-72. DOI: 10.1016/s0005-2736(97)00275-7. View

15.

Connor J, Yatvin M, Huang L . pH-sensitive liposomes: acid-induced liposome fusion. Proc Natl Acad Sci U S A. 1984; 81(6):1715-8. PMC: 344989. DOI: 10.1073/pnas.81.6.1715. View

16.

Meng F, Hennink W, Zhong Z . Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials. 2009; 30(12):2180-98. DOI: 10.1016/j.biomaterials.2009.01.026. View

17.

Kikumori T, Kobayashi T, Sawaki M, Imai T . Anti-cancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res Treat. 2008; 113(3):435-41. DOI: 10.1007/s10549-008-9948-x. View

18.

Owens 3rd D, Peppas N . Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm. 2005; 307(1):93-102. DOI: 10.1016/j.ijpharm.2005.10.010. View

19.

Rejman J, Oberle V, Zuhorn I, Hoekstra D . Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J. 2003; 377(Pt 1):159-69. PMC: 1223843. DOI: 10.1042/BJ20031253. View

20.

Torres A, Gait M . Exploiting cell surface thiols to enhance cellular uptake. Trends Biotechnol. 2012; 30(4):185-90. DOI: 10.1016/j.tibtech.2011.12.002. View